PRL-3 induces a positive signaling circuit between glycolysis and activation of STAT1/2.

The FEBS Journal
Esten N VandsembPegah Abdollahi

Abstract

Multiple myeloma (MM) is an incurable hematologic malignancy resulting from the clonal expansion of plasma cells. MM cells are interacting with components of the bone marrow microenvironment such as cytokines to survive and proliferate. Phosphatase of regenerating liver (PRL)-3, a cytokine-induced oncogenic phosphatase, is highly expressed in myeloma patients and is a mediator of metabolic reprogramming of cancer cells. To find novel pathways and genes regulated by PRL-3, we characterized the global transcriptional response to PRL-3 overexpression in two MM cell lines. We used pathway enrichment analysis to identify pathways regulated by PRL-3. We further confirmed the hits from the enrichment analysis with in vitro experiments and investigated their function. We found that PRL-3 induced expression of genes belonging to the type 1 interferon (IFN-I) signaling pathway due to activation of signal transducer and activator of transcription (STAT) 1 and STAT2. This activation was independent of autocrine IFN-I secretion. The increase in STAT1 and STAT2 did not result in any of the common consequences of increased IFN-I or STAT1 signaling in cancer. Knockdown of STAT1/2 did not affect the viability of the cells, but decreased PRL-3-i...Continue Reading

References

Oct 6, 1998·Annual Review of Biochemistry·G R StarkR D Schreiber
Dec 12, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J C RathmellC B Thompson
May 27, 2003·Apoptosis : an International Journal on Programmed Cell Death·M Chawla-SarkarE C Borden
Feb 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nikolai N KhodarevRalph R Weichselbaum
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
May 27, 2006·Blood·Fenghuang ZhanJohn D Shaughnessy
Jul 29, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L WangC Shou
Oct 31, 2006·International Journal of Cancer. Journal International Du Cancer·Mårten FryknäsAnders Isaksson
Sep 8, 2007·The Journal of Clinical Investigation·Venugopalan CheriyathErnest C Borden
Jan 29, 2008·Cancer Metastasis Reviews·Darrell C BessetteCatherine J Pallen
Nov 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ralph R WeichselbaumAndy J Minn
May 30, 2009·Proceedings of the National Academy of Sciences of the United States of America·Hyeonjoo Cheon, George R Stark
Jun 9, 2009·PloS One·Nikolai N KhodarevRalph R Weichselbaum
Dec 15, 2010·Current Drug Targets·Teh Liane KhooJohn Gibson
Oct 27, 2011·Molecular Cancer Therapeutics·Jun-Jie ChenBaolin Zhang
Apr 11, 2012·International Journal of Cancer. Journal International Du Cancer·Atsushi HosuiTetsuo Takehara
May 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikolai N KhodarevRalph R Weichselbaum
Jun 30, 2012·Nature Methods·Johannes SchindelinAlbert Cardona
Dec 4, 2012·Nucleic Acids Research·Irina RusinovaPaul J Hertzog
Apr 17, 2013·BMC Bioinformatics·Edward Y ChenAvi Ma'ayan
Feb 22, 2014·Annual Review of Immunology·William M SchneiderCharles M Rice
Mar 4, 2014·Expert Opinion on Therapeutic Targets·Amanda M Campbell, Zhong-Yin Zhang
Dec 17, 2014·Immunological Reviews·Yawara KawanoIrene M Ghobrial
Dec 18, 2014·Genome Biology·Michael I LoveSimon Anders
May 5, 2016·Nucleic Acids Research·Maxim V KuleshovAvi Ma'ayan
Oct 5, 2016·Molecular Cancer Research : MCR·Pegah AbdollahiMagne Børset
Mar 7, 2017·Nature Methods·Rob PatroCarl Kingsford
Jun 9, 2017·Nature·Wilhelm Palm, Craig B Thompson
Jul 21, 2017·Nature Reviews. Disease Primers·Shaji K KumarKenneth C Anderson
Mar 1, 2018·The Biochemical Journal·Atsushi YoshidaHiroaki Miki
Apr 14, 2018·Experimental Hematology & Oncology·Magnus Aassved HjortTorstein Baade Rø

❮ Previous
Next ❯

Citations

Nov 3, 2021·Current Opinion in Clinical Nutrition and Metabolic Care·Pegah AbdollahiMagne Børset

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.